"Top Biotech Stock to Buy After Missing Out on Novo Nordisk"

Viking Therapeutics' stock surged after positive phase 2 trial results for its weight loss medication, VK2735, which showed promising efficacy compared to Novo Nordisk's Wegovy and Eli Lilly's Zepbound. With ample cash reserves and ongoing R&D, Viking is poised to compete in the obesity care market, offering potential for investors despite being a latecomer. Meanwhile, Novo Nordisk and Eli Lilly continue to dominate the market, signaling ongoing opportunities for investment.